Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys

The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Ele­vidys, after three patients died from liver failure after taking it or a similar treatment.

More From Author

Is AI Behind These In-House Microsoft Layoffs? — See Also

NYT Connections hints and answers for Saturday, July 19 (game #769)

Leave a Reply

Your email address will not be published. Required fields are marked *